Adagio Therapeutics Inc Aktie News

NEW HAVEN, Conn., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 2:35 p.m. ET in Miami, FL.

NEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced it has identified and nominated for preclinical development a potentially best-in-class monoclonal antibody candidate for the prevention of Respiratory Syncytial Virus (RSV) among neonates, infants, and children. Invivyd's investigational antibody, VBY329, was generated by Invivyd's proprietary anti...

Invivyd, Inc. remains a Hold rating as it advances its monoclonal antibody pipeline, notably VYD2311 as a Covid-19 vaccine alternative. VYD2311 offers broader patient coverage and intramuscular dosing, with phase 3 DECLARATION and LIBERTY trials set to begin by end of 2025; Topline data mid-2026. Company's technology shows strong variant-neutralization, and expansion into RSV and measles preven...

NEW HAVEN, Conn., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced the pricing of an underwritten public offering of 44,000,000 shares of its common stock at an offering price of $2.50 per share and, to certain investors, in lieu of common stock, pre-funded warrants to purchase 6,000,000 shares of its common stock at a price of $2.4999 per pre-funded warr...

NEW HAVEN, Conn., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Invivyd intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the shares of Invivyd common stock sold in the public offering at the public ...

Invivyd, Inc. ( IVVD ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Katie Falzone Marc Elia Timothy Lee - Chief Commercial Officer William Duke - CFO, Principal Accounting Officer & Principal Executive Officer Conference Call Participants Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Patrick Trucchio - H.C. Wainwright & Co, LLC, Research Division Presen...

NEW HAVEN, Conn., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the quarter ended September 30, 2025, and provided recent business highlights.

NEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, November 6, 2025, at 8:30 a.m. ET to discuss its third quarter 2025 financial results and provide a corporate update.